{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T03:54:33Z","timestamp":1774842873687,"version":"3.50.1"},"reference-count":20,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,9,18]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Individuals with psoriasis (PsO) or psoriatic arthritis (PsA) have an elevated risk of major adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardial infarction (MI), and cerebrovascular accident (CVA). Biologic disease-modifying antirheumatic drugs (bDMARDs) may reduce cardiovascular risk; however, whether MACE risk differs by bDMARD class for this population is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from TriNetX database, we identified patients with PsO\/PsA who were new bDMARD users, including tumor necrosis factor inhibitors (TNFi), interleukin (IL)-17A inhibitors (\u2212i), IL-23i, or IL-12\/23i. Time-dependent risk for MACE was calculated using weighted multinomial Cox proportional hazards regression with TNFi exposure as the referent. Additional analyses evaluated components of the primary outcome and baseline cardiovascular disease. A negative control outcome was used to assess bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 32,758 patients with PsO\/PsA who were new bDMARD users. Patients had PsO\/PsA for a mean of 3.5 (SD 4.5) years prior to starting a biologic, the most common being TNFi (62.9%), followed by IL-17i (15.4%), IL-23i (11%), and IL-12\/23i (10.7%). In weighted multinomial Cox proportional hazards regression, the adjusted risk of MACE was similar for IL-17Ai (adjusted hazard ratio [aHR] 0.98, 95% CI 0.73-1.32), IL-23i (aHR 0.84, 95% CI 0.54-1.31), and IL-12\/23i (aHR 1.08, 95% CI 0.80-1.47) as compared to TNFi. Subset analyses supported the primary analysis. Negative control outcomes suggested adequate control of bias confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MACE risk does not significantly differ across bDMARD classes in patients with PsO\/PsA. Therefore, cardiovascular risk should not guide biologic selection in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0446","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:25:24Z","timestamp":1759321524000},"page":"277-282","source":"Crossref","is-referenced-by-count":1,"title":["Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events"],"prefix":"10.3899","volume":"53","author":[{"given":"Jack","family":"Geiger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonit","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-2450","authenticated-orcid":false,"given":"Jean","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9699-4000","authenticated-orcid":false,"given":"Michael","family":"Putman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2026032910412620000_53.3.277.1","doi-asserted-by":"crossref","first-page":"829709","DOI":"10.3389\/fcvm.2022.829709","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026032910412620000_53.3.277.2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12768"},{"key":"2026032910412620000_53.3.277.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02310.x"},{"key":"2026032910412620000_53.3.277.4","doi-asserted-by":"crossref","first-page":"2321194","DOI":"10.1080\/09546634.2024.2321194","article-title":"Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-\u03b1 and interleukin-12\/23 inhibitors: a nationwide population-based cohort study in Korea","volume":"35","author":"Cho","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026032910412620000_53.3.277.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-014-0490-y"},{"key":"2026032910412620000_53.3.277.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"2026032910412620000_53.3.277.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23094"},{"key":"2026032910412620000_53.3.277.8","doi-asserted-by":"crossref","unstructured":"Dotan A , Ben-Shabbat N , Watad A , McGonagle D , Amital H. Biological therapies for psoriasis and psoriatic arthritis- effects on future risk development of major adverse cardiovascular events (MACE) [abstract]. Arthritis Rheumatol 2023; 75 Suppl 9.","DOI":"10.1136\/annrheumdis-2023-eular.6255"},{"key":"2026032910412620000_53.3.277.9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-016-3487-2","article-title":"Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms","volume":"37","author":"Yim","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026032910412620000_53.3.277.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2026032910412620000_53.3.277.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798"},{"key":"2026032910412620000_53.3.277.12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology"},{"key":"2026032910412620000_53.3.277.13","unstructured":"Mirza M , Putman M , Singla S , Liew JW. Secular trends in biologic prescribing for psoriasis and psoriatic arthritis, 2014-2024. Arthritis Rheumatol Apr 23 (Epub ahead of print)."},{"key":"2026032910412620000_53.3.277.14","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2026032910412620000_53.3.277.15","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026032910412620000_53.3.277.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.30"},{"key":"2026032910412620000_53.3.277.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01308.x"},{"key":"2026032910412620000_53.3.277.18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/life11090919","article-title":"Impact of interleukin-17 inhibitor therapy on arterial intima-media thickness among severe psoriatic patients","volume":"11","author":"Piros","year":"2021","journal-title":"Life"},{"key":"2026032910412620000_53.3.277.19","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1068950"},{"key":"2026032910412620000_53.3.277.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:41:46Z","timestamp":1774806106000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.3899\/jrheum.2025-0446"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0446","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}